RhumbLine Advisers
LOGC

RhumbLine Advisers’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

RhumbLine Advisers’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,340
Closed -$97K – 3158
2021
Q1 		$97K Buy
13,340
+175
+1% +$1.44K ﹤0.01% 2937
2020
Q4 		$100K Buy
13,165
+1,720
+15% +$11.5K ﹤0.01% 2967
2020
Q3 		$104K Sell
11,445
-2,075
-15% -$15.7K ﹤0.01% 2860
2020
Q2 		$114K Buy
13,520
+3,320
+33% +$21.8K ﹤0.01% 2938
2020
Q1 		$50K Hold
10,200
– – ﹤0.01% 2863
2019
Q4 		$73K Buy
10,200
+200
+2% +$1.81K ﹤0.01% 2899
2019
Q3 		$108K Sell
10,000
-75
-0.7% -$802 ﹤0.01% 2875
2019
Q2 		$131K Buy
+10,075
New +$134K ﹤0.01% 2886

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

RhumbLine Advisers's LOGC Position: Q2 2021 in Review

RhumbLine Advisers sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 13,340 shares — an estimated $97K sold.

RhumbLine Advisers first reported a position in LOGC in Q2 2019 and held it in 8 quarters. The position peaked at $131K in Q2 2019. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • RhumbLine Advisers reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • RhumbLine Advisers sold 13,340 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $97K.
  • RhumbLine Advisers first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2019 and held it in 8 quarters.
  • RhumbLine Advisers's LogicBio Therapeutics, Inc. Common Stock position peaked at $131K in Q2 2019.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.